Actively Recruiting
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
Led by Arcutis Biotherapeutics, Inc. · Updated on 2026-01-14
16
Participants Needed
5
Research Sites
59 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.
CONDITIONS
Official Title
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and females aged 2 to under 12 years at Day 1
- Clinical diagnosis of psoriasis vulgaris for at least 2 months at Screening
- Scalp psoriasis with at least moderate severity on Investigator Global Assessment at Day 1
- Body psoriasis with at least mild severity on Investigator Global Assessment at Day 1
- Scalp psoriasis involving 10% or more of total scalp at Day 1
- Body psoriasis involving at least 3% body surface area (BSA) at Day 1
You will not qualify if you...
- Unable to stop medications and treatments before Day 1 (first application of study drug)
- Current diagnosis of non-plaque psoriasis or drug-induced psoriasis
- Significant active infection or infection requiring antibiotics, antifungal, or antiviral treatment within 7 days prior to Day 1
- Skin conditions other than psoriasis vulgaris interfering with study evaluations
- Unable to stop strong CYP3A4 inhibitors for 2 weeks before Day 1 and during study
- History of severe kidney problems, moderate to severe liver disorders, or chronic infections like hepatitis B, hepatitis C, or HIV
- Family members of the study staff or sponsor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Arcutis Clinical Study Site 106
Bryant, Arkansas, United States, 72022
Actively Recruiting
2
Arcutis Clinical Study Site 107
Miami Lakes, Florida, United States, 33014
Actively Recruiting
3
Arcutis Clinical Study Site 108
Meridian, Idaho, United States, 83646
Actively Recruiting
4
Arcutis Clinical Study Site 105
West Lafayette, Indiana, United States, 47906
Actively Recruiting
5
Arcutis Clinical Study Site 104
Arlington, Texas, United States, 76011
Actively Recruiting
Research Team
A
Arcutis Biotherapeutics
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here